34781
document
[ Specific T cell immune response in chronic hepatitis B patients treated with different doses of recombinant hepatitis B vaccine ] . OBJECTIVE To study the specific cellular immunoresponse of peripheral blood lymphocytes in the chronic hepatitis B patients treated with different doses of recombinant hepatitis B vaccine . METHODS Seventy-two chronic hepatitis B patients who did not use any anti-HBV drugs within 6 months were randomized into 3 groups ( 90 micrograms , 60 micrograms , and placebo ) in a ratio of 1:1:1 . The patients in different groups were treated with different doses of recombinant hepatitis B vaccine in combination with IFN alpha 1b 50 micrograms with 3 times a week for 24 weeks . All patients were followed up for 24 weeks ( W24 ) . HBV DNA , HBeAg and liver functions were detected at different time points , and the number of cells that secrete IFN-gamma were detected by ELISPOT . RESULTS There were no significant difference in ELISPOT positive ratio among the 3 groups on baseline detection . At W24 , 12 cases , 12 cases , and 7 cases showed ELISPOT positive in the group of 90 micrograms , 60 micrograms , and placebo . The proportion of patients who were ELISPOT positive was higher in the groups treated with recombinant hepatitis B vaccine ( including the dose of 90 micrograms and 60 micrograms ) than that in the placebo group ( P=0.0446 ) . HBV DNA turned negative in 6/24 of the patients treated with recombinant hepatitis B vaccine ( at both the doses of 90 micrograms and 60 micrograms ) , and HBeAg/Anti-HBe seroconversion or HBeAg became negative in 7/24 of them . In the placebo group , none of the patients showed undetectable HBV DNA , HBeAg/Anti-HBe seroconversion or HBeAg disappearance . At the 24W of follow up , in the patients who were ELISPOT positive , HBV DNA became undetectable in 4 of the patients treated with recombinant hepatitis B vaccine ( at doses of 90 micrograms and 60 micrograms ) , and HBeAg/Anti-HBe seroconversion or HBeAg disappearance were found in 9 of the cases . In the placebo group , none of the cases showed undetectable HBV DNA , and only 1 case had HBeAg/Anti-HBe seroconversion . CONCLUSION The recombinant hepatitis B vaccine may increase the function of specific T lymphocytes in patients with chronic hepatitis B . There were no significant differences between the patients treated with the dose of 90 micrograms and 60 micrograms hepatitis B vaccine .
34782
Intervention_Pharmacological
recombinant hepatitis B vaccine
34783
Intervention_Pharmacological
recombinant hepatitis B vaccine
34784
Intervention_Control
placebo )
34785
Intervention_Pharmacological
different doses of recombinant hepatitis B vaccine in combination with IFN alpha 1b 50 micrograms with 3 times a week for 24 weeks
34786
Intervention_Pharmacological
recombinant hepatitis B vaccine
34787
Outcome_Physical
Specific T cell immune response
34788
Outcome_Physical
specific cellular immunoresponse
34789
Outcome_Physical
HBV DNA , HBeAg and liver functions
34790
Outcome_Physical
secrete IFN-gamma
34791
Outcome_Physical
ELISPOT
34792
Outcome_Physical
ELISPOT positive ratio
34793
Outcome_Physical
ELISPOT positive
34794
Outcome_Physical
ELISPOT positive
34795
Outcome_Physical
HBV DNA
34796
Outcome_Physical
HBeAg/Anti-HBe seroconversion or HBeAg
34797
Outcome_Physical
undetectable HBV DNA , HBeAg/Anti-HBe seroconversion or HBeAg disappearance
34798
Outcome_Physical
ELISPOT positive
34799
Outcome_Physical
HBV DNA
34800
Outcome_Physical
HBeAg/Anti-HBe seroconversion
34801
Outcome_Physical
HBeAg disappearance
34802
Outcome_Physical
HBV DNA
34803
Outcome_Physical
HBeAg/Anti-HBe seroconversion
34804
Outcome_Physical
function of specific T lymphocytes
34805
Participant_Condition
chronic hepatitis B patients